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HPV (Human Papilloma Virus) 16 is the most frequent HPV type
found in invasive cervical carcinoma (ICC) in Russian women
(Samoylova, 1995; van Muyden, 1999). Although infection with
HPV16 and some other high/intermediate-risk types of HPV such
as HPV18, 31, 33 etc. is considered a main risk factor for ICC and
cervical intraepithelial neoplasia (CIN), only a minority of women
with infection by these types of HPV develop any disease (Munoz
et al, 1992; Eluf et al, 1994; Bosch et al, 1995; Matsukura and
Sugase, 1995). Specific HPV16 variations located in E6, E7, E2,
E5, L1, L2 or the long control region (LCR) have been associated
with viral persistence and development of high-grade cervical
lesions (Xi et al, 1995; Yamada et al, 1995; Londesborough et al,
1996; Wheeler et al, 1997). HPV16 E6 and E7 encode oncopro-
teins able to interact with regulatory proteins such as p53 and pRb;
they are regarded as the major if not the only genes responsible for
neoplastic transformation (Dyson et al, 1989; Werness et al, 1990;
Phelps et al, 1992; von Knebel Doeberitz et al, 1994). 
Sequence variations are frequent particularly in HPV16 E6
(Alvarez-Salas et al, 1995; Xi et al, 1995; Yamada et al, 1995–1997;
Londesborough et al, 1996; Xi et al, 1997; Zehbe et al, 1998). The
variants are reported to have different biological and biochemical
properties. Londesborough found that only 1 of 16 women
infected with the HPV16 prototype developed CIN or ICC; in
contrast, 10/12 women infected with HPV16 E6 variants had
persistent infection which is associated with development of CIN
and ICC (Londesborough et al, 1996). Zehbe concluded that
sequence variation in HPV16 E6 predicted risk of progression
from CIN III, because 15/16 cases of ICC contained variant E6 in
contrast to CIN III where only 11/25 had variant E6 (Zehbe et al,
1998). Alvarez-Salas showed that variants of HPV 16 E6 correl-
ated positively with clinical aggressiveness (Alvarez-Salas et al,
1995). Stöppler displayed that variants of HPV 16 E6 protein
differed in the abilities to suppress keratinocyte differentiation and
to induce P53 degradation in vitro (Stoppler et al, 1996). However,
the rate, the type and the biological and clinical significance of the
variations in HPV 16 E6 have not been geographically uniform,
which might be explained by the geographically different distribu-
tion of the HLA polymorphisms (Ellis et al, 1995). The HPV 16
E6 variations in cervical samples from Russian women has not
been studied previously and in this work we have examined HPV
16 E6 in ICC and CIN from Russian pattients. 
The definition of ‘variant’ has been a source of confusion in
previous studies, because it has been based on all departures from
the original ‘prototype’ once isolated randomly from a case of ICC.
Among the 50 HPV16-positive cases out of 104 Russian patients,
we show that there were two major forms of E6, one of which was
the international prototype, as reported by other studies (Yamada
et al, 1997; Zehbe et al, 1998). They differ from each other only at
nt 350 with either a guanine (29/50 cases) or a thymidine (‘proto-
type’, 9/50 cases) residue. A third heterogeneous variant group
(12/50 cases) with apparently genuine mutations on the background
of the two major forms was defined. Application of this scheme
failed to substantiate that different configurations of E6 determine
progression from CIN to ICC among Russian patients. 
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Summary HPV16 is frequently seen in invasive cervical cancer (ICC) and cervical intraepithelial neoplasia (CIN). Its E6 gene has frequent
sequence variations. Although some E6 variants have been reported to have different biochemical or biological properties, they do not show
geographical identity. Moreover, the definition of ‘variant’ has been a source of confusion because it has been based on all departures from
the ‘prototype’ once isolated randomly from an ICC case. We amplified the HPV16 E6 gene by PCR from fresh-frozen tissue of 104 cases of
ICC and CIN from Russian patients and sequenced it in positive cases. We found that 32 of 55 (58.2%) ICC cases and 18 of 49 (36.7%) CIN
cases were HPV 16-positive and we could identify 3 groups of E6 variants: group A was characterized by G at nt 350 where group B had T,
and group M was a heterogeneous mixture of unique E6 variants; no significant difference existed in the distribution of the different groups
between ICC and CIN; the clinically malignant (as defined by FIGO stage) order between the groups was M > A > B in ICC; in the cases with
a single HPV16 E6 sequence, coexisting ICC, CIN and normal epithelium in the same patient shared the E6 variant; and 4 cases of ICC had
double/multiple E6 variants. The results did not show any importance of E6 variants for ICC progression in Russian women. The results also
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MATERIALS AND METHODS 
Patients 
We collected 104 cases, including 55 cases of primary invasive
squamous cell carcinoma and 49 cases of CIN, from patients
undergoing radical hysterectomy at the Blokhin Cancer Research
Center, Moscow, Russia in the period from 1994 to 1998. Among
the collected cases, the HPV16-positive cervical specimens as
determined by PCR analysis were selected to perform the HPV16
E6 sequence variation test, where 32 out of 55 (58.2%) ICC cases
and 18 out of 49 (36.7%) CIN cases were HPV16 positive. The age
range was 30–80 (mean 43.8) for the HPV16-infected patients
with ICC and 31–43 (mean 37.2) for those with CIN. The FIGO
(the standard of the International Federation of Gynecology and
Obstetrics subdivides the cervical carcinoma cases into stages I to
IV) (Sparen et al, 1995) stage and degree of differentiation (high,
moderate or low) were recorded at the Blokhin Cancer Research
Center. 
Tumour samples were snap-frozen in liquid nitrogen. Part of
each sample was transferred on dry-ice to the Department of
Genetics and Pathology, Uppsala University, Sweden. This project
had received official institutional and ethical approval. 
Microdissection and DNA preparation 
Sections (6 mm) were prepared from the fresh tissue and stained
with Mayer’s haematoxylin. CIN and invasive cancer nests were
microdissected (Hedrum et al, 1994). CIN presented simultan-
eously with invasive cancer in 7 surgical specimens, so multiple
microdissections were then performed from CIN, the invasive
cancer and normal squamous epithelium. 7 other cases of invasive
cancer were also multiply microdissected. All lesions were sharply
demarcated from stroma or adjacent normal epithelium.
Admixture by normal cells was insignificant as judged by exami-
nation under microscope. The blade of the scalpel was changed
after each microdissection. The dissected pieces were transferred
to Eppendorf tubes containing 30 ml 1 ´ PCR buffer II (PE, Roche
Molecular System, NJ). Each sample contained 500–1000 cells.
Digestion by proteinase K (500 mg ml–1) at 55˚C for 4 hours was
interrupted by incubation at 95˚C for 10 min. Quality of the
prepared DNA was checked by PCR amplification of micro-
satellite markers. 
Polymerase chain reaction 
PCR primers for HPV16 E6 were 5¢-CGTAACCGAAATCG-
GTTGAAC-3¢ and 5¢-GCTCATAACAGTAGAGATC-3¢ (Yamada
et al, 1995). We performed PCR on a RoboCycler Gradient 96
(STRATAGENE) in 50 ml volume (1 ´ PCR buffer II, 2.5 mM
MgCl2, 200 mM of each deoxynucleotide, 0.5 U Taq DNA poly-
merase (PE, Roche Molecular System, NJ), 0.5 mM of each sense
and anti-sense primer, and 5 ml DNA solution) with a 35 cycle
protocol: 1 min denaturation at 95˚C, annealing at 55˚C and exten-
sion at 72˚C, with 5 min initial denaturation at 95˚C and 7 min
final elongation at 72˚C. 
To avoid contamination, we prepared PCR master mix in an
isolated room under a hood where UV light was used to destroy
any potential contaminating DNA or PCR product at the working
area before and after this manipulation and then added template
DNA under similar working conditions in a separate room. 
Sequence analysis 
PCR amplicons were electrophoretically separated on 1.5%
agarose gel and stained with ethidium bromide. Desired bands
were cut out with subsequent purification on GenElute Minus EtBr
Spin Columns (SUPELCO, Bellefonte, PA). The purified PCR
products were quantified and then applied to enzymatic extension
reactions for DNA sequencing using the Cycle Sequencing Ready
Reaction Kit (Big-Dye terminator reagent (PE Applied Biosystems)
containing dye-labelled terminators) in GeneAmp PCR Systems
9600 (PE, Norwalk, CT). The same forward and reverse primers as
for the PCR amplification of E6 were used separately in cycle
sequencing. The extension products were purified by ethanol/-
sodium acetate precipitation, then electrophoresed on an ABI
Prism 377 sequencer. The sequence and variations were analysed
and determined by the FacturaTM and Sequence Navigator
version 2.0 (PE Applied Biosystems). 
The test was repeated once for each sample starting from DNA-
PCR amplification with the same result. 
Statistical analysis 
The Chi-square test was used to assess the relation of the preval-
ence of different variant groups between ICC and CIN. The rank
sum test was used to judge the relation of the variants with the
FIGO stages. 
RESULTS 
Prevalence of HPV 16 E6 variations 
32 cases of ICC and 18 cases of CIN were analysed for HPV16 E6
sequence variation (Figure 1). 
Any E6 sequence isolated was here defined as variant. All CIN
and 28 out of 32 ICC cases had a single E6 variant; the remaining
4 cases of ICC carried double/multiple E6 variants. The E6 vari-
ants were classified as three groups, A, B and M. A and B were
identical except for the polymorphic nt 350, which was either
guanine (group A) or thymidine (group B). Group M was a
mixture of variants with sequence departures from group A and/or
B at other sites than nt 350. The 4 cases with double/multiple E6
isolates were assigned to group M. 
Group A dominated both in cases of ICC (19/32; 59.4%) and
cases of CIN (10/18; 55.5%). Group B, which corresponded to the
international ‘prototype’, occurred in 5/32 (15.6%) cases of ICC
and 4/18 (22.2%) cases of CIN. The third group (M) was repre-
sented by 8/32 (25%) cases of ICC and 4/18 (22.3%) cases of CIN.
There was no statistically significant difference in the distribution
of groups A, B and M between CIN and ICC. 
Many studies categorize HPV16 E6 sequences into only two
groups, ‘prototype’ and ‘variants’ group. When these previous
categories were applied to our data, the ‘variants’ group accounted
for 27/32 (84.4%) cases of ICC and 14/18 (77.7%) cases of CIN,
respectively. No significant difference in the distribution of the
‘prototype’ group and ‘variants’ group was found between CIN
and ICC. 
Relation of HPV 16 E6 variants to the FIGO stages of
ICC 
Among 32 cases of ICC, 4 cases in group A and one case in group
M were unknown for FIGO stage. The relation of HPV16 E6HPV16 E6 gene variations in cervival cancer 793
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variants to the FIGO stage of ICC is shown in Table 1. Group B
was mainly associated with cancers detected in early clinical
stages. Group A, the most common one, was represented in early
as well as advanced stages. The M group was not seen in FIGO
stage I. Differences between the groups were statistically signifi-
cant indicating that the order of clinical malignancy between the
groups would be M > A > B. 
HPV 16 E6 variants at nt 350 in synchronous lesions or
multiple samples of ICC 
Since nt 350 was the most common polymorphic site, this section
would mainly focus on description of nucleotide variations at this
site in 14 out of 32 cases of ICC with synchronous lesions or
multiple samples available (Table 2). Among these cases, 10
contained a single HPV16 E6 isolate. The E6 variant in these cases
was concordant from different parts of each ICC case. When CIN
was also present (N3, M2, M21), all samples from these precursors
had the same variant as in the simultaneously found invasive
cancer. Normal squamous epithelium sampled in case M19 and N3
showed the same variant as in the invasive cancers. 
4 cases (M4, M12, M13, M23) carried double/multiple E6 vari-
ants, M12 was an invasive cancer with G (one sample), T (one
sample) or G + T (one sample). In M4, the CIN II lesion had either
G (4 samples) or T (one sample); the synchronous invasive cancer
had G in 2 but T in one sample; and the variants were identical in
the CIN II samples and the samples from the invasive cancer. M13
presented T in 3/3 samples from its CIN II; and in the invasive
cancer, one sample showed G and another sample T at nt 350 with
an additional missense variation from T to G at nt 310. M23
showed T in the only sample from normal epithelium; of two CIN
II samples, one showed G at nt 350, another showed T at nt 350
with an additional change of C to T at nt 374 which created a stop
signal; the invasive cancer had either T (2 samples) or G (2
samples). 
Double/multiple HPV16 E6 variants detected in a single case
might be considered as the result of PCR artifacts or contamina-
tion. However, this could be easily ruled out because of the
following facts: the specimens used were fresh specimens which
are quite safe not to introduce PCR artifacts (Williams et al, 1999);
every step of the PCR preparation procedure was manipulated very
strictly in order to avoid any potential contamination; the test
was repeated with the same result; there were 4 cases with
double/multiple variants; more than one sample in M4, M13 and
M23 had E6 variants with either G or T at nt 350; out of 23
samples from these 4 cases, 22 showed the variant with a single G
or T signal at nt 350, and only one showed G + T which might
occur at a time when the microdissected sample is derived from 2
overlapping sets of cells with different HPV variants. 
Open reading frame Predicted amino acid Number of cases 
CIN ICC 
@1 1 1 22 223333 4 5
0 4 8 17 881357 5 3  
9 5 8 56 690504 2 2
#T G G C A T A T C T CA A  
A – – – – – – – – – G – – – L83V 10 19 
B – – – –– –––––– – – – 4 5  
M – – A – – – – – – G – – – E29K/L83V 1 0 
– – – T – – – – – G – – – L38L/L83V 1 0 
– – – – T – – – – – – – – N58I 1 0 
– – – – – – – – – G – T – L83V/R117G 1 0 
C – – – – – – – – G – – – F2F/L83V 0 1 
– T – – – A G – T G – – – Q14H/A61A/V62V/H78Y/L83V 0 2 
– – – – – – – – – G – – – L83V 
– – – – – – – – – – – – – – 0 1 (M13) 
– – – – – – – G – – – – – F69L 
– – – – – – – – – G – – – L83V 
– – – – – – – – – – – – – – 0 2 (M4, M12) 
– – – – – – – – – G – – – L83V 
– – – – – – – – – – – – – – 0 1 (M23) 
– – – – – – – – – – T – – Q91Stop codon 
– – – – – – – – – G – – G L83V/S143S 0 1 
18 32
{
{
{
Figure 1 Sequence variations of HPV 16 E6 in CIN and ICC. @: nucleotide positions are indicated vertically, e.g., 109, 111, and so forth. #: reference
nucleotides. –, presents the reference nucleotide at this position. The position of amino acid is stated numerically. The letter preceding this number refers to the
reference amino acid, and the letter after it refers to the amino acid predicted from the nucleotide sequence found. A, B and M, are the given names of the
variant groups. The square brackets to the left group together the multiple variants found in M13, M4, M12 and M23, respectively
Table 1 Relation of HPV16 E6 variant groups with FIGO stage 
FIGO stage A B M 
Ia 2 2 0 
Ib 3 2 0 
IIa 3 1 1 
IIb 1 0 1 
III 5 0 3 
IV 1 0 2 
Total 15 5 7 
Rank sum test (two sides), P < 0.05 between A and B; P < 0.05 between A
and M; and P < 0.005 between B and M. 794 X Hu et al 
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DISCUSSION 
The present HPV16 E6 variations in Russian patients were similar
to other results (Londesborough et al, 1996; Yamada et al, 1997;
Zehbe et al, 1998). The pattern of nucleotide substitutions leads us
to propose 3 categories of sequences in the HPV16 E6 genome.
Some previous investigators have used the ‘prototype’ sequence,
which corresponds to our group B, as a yardstick and labelled all
departure ‘variants’. We found that the nucleotide sites differ
principally from each other. Nt 350 behaves as a polymorphic site
where roughly two thirds of the isolates have a G and the
remainder a T. The other sites register as classical variants with
one or occasionally two departures from a predominant configura-
tion. This classification permits a logical division into two homo-
genous groups (A and B) supplemented by one heterogeneous
group M. Failure to have noted this is the major reason for a
confused literature based on lumping together all ‘pure non-T’ at
nt 350 with all other departures from the sequence of the proto-
type. When our groups A, B and M are applied, the distribution of
the 3 groups in invasive cancer and CIN is identical. This contrasts
with claims that E6 variants at nt 350 have a higher prevalence in
invasive cancer than in CIN III. Therefore, our findings do not
support the conclusion that ‘variants’ of E6 are more likely to
cause progression to invasive cancer than ‘prototype’ E6 (Zehbe
et al, 1998). 
Even if the previous scheme (Zehbe et al, 1998) which classi-
fied E6 variants as two groups, ‘prototype’ group and ‘variants’
group, is applied on our cases, no difference in the distribution of
the E6 groups can be seen between CIN and ICC in cervical
samples from Russian patients. 
Sampling bias might affect the judgement of the E6 variant
distribution. We collected 104 cases of CIN and ICC from
Moscow during the period from 1994 to 1998. Our cases seem to
be representative of the selected population because 58.2% of ICC
and 36.7% of CIN samples were found to be HPV16 positive,
which is similar to the results of other larger studies on Russian
cases and world wide (Bosch et al, 1995; Matsukura and Sugase,
1995; van Muyden, 1999). 
Circulating HPV16 E6 variants might shift during a specified
period of time. Among our cases, the mean age of patients with
ICC was 6.6 years higher than that of patients with CIN, which
means ICC and CIN might carry different circulating E6 variants
from different periods. Unfortunately, we could not exclude this
possibility concerning fluctuations in the distribution of HPV16
variants over time within the population. The question if such fluc-
tuations do occur has not been addressed in detail in the literature. 
Our results are consistent with many other recent findings that
HPV16 E6 ‘variants’ and ‘prototype’ have an equally malignant
potential (Bontkes et al, 1998; Luxton et al, 2000). To finally
elucidate the E6 variants-associated disease outcomes, longitud-
inal cohort studies should be conducted. To some extent, the
multiple microdissections of the synchronous lesions performed
here might mimic longitudinal cohort studies. The use of E6
genomic markers has permitted an insight into persistence of the
same variant in different lesions of the same patient. The overall
impression is that the same variant will be present in the entire
chain leading from normal epithelium via CIN to invasive cancer
in the cases with a single E6 sequence variant. These findings are
identical to conditions in Swedish women (Hu et al, 1999) and
support the relevance of the cross-sectional study. 
In 4 cases (M4, M12, M13 and M23) of ICC, mixtures of two or
more different E6 genomes are disclosed. Two explanations can be
offered: either the patients have been multiply infected or the
second and/or third variant is/are derived from the original HPV16
isolate by mutations within the patient herself. In general, the
common polymorphic variations at nt 350, T or G, are less likely
to have been substituted for each other within a certain patient
because the mutation at this site might have occurred long ago, and
then either T or G was naturally selected and kept stable to preval-
ently circulate. Since T and G variants at nt 350 of E6 are so
common, it should not be difficult for one patient to pick up both
variants in repeated infections. M12 presents two different E6
genomes in the invasive cancer, and M4 shows two E6 variants
both in CIN and invasive cancer. These two cases could represent
double infections. In contrast, the results of M13 and M23 were
much more complicated. It seems to us that the results were
compatible with events where the second and/or third variants
were derived from the original infection by mutations. M13 seems
to have a putative parental E6 variant with T at nt 350 in the
invasive cancer, and in this variant a mutation at nt 310 from T to
G occurs. M23 seems to be originally infected by an E6 variant
with T at nt 350 which presents in the normal epithelium, in the
Table 2 HPV 16 E6 variants at nt 350 in synchronous lesions and multiple microdissected samples of invasive cancer 
Case Normal CIN I CIN II CIN III ICC 
M1 – – – – G 3/3 
M3 – – – – G 3/3 
M6 – – – – G 2/2 
M8 – – – – G 2/2 
M15 – – – – G 2/2 
M25 – – – – G 2/2 
M19 G 2/2 – – – G 2/2 
N3 G 2/2 G 1/1 G 2/2 G 2/2 G 4/4 
M2 – – – T 1/1 T 3/3 
M21 – – T 1/1 – T 4/4 
M12 – – – – G 1/3, T 1/3, T+G 1/3 
M4 – – G 4/5, T 1/5 – G 2/3, T 1/3 
M13 – – T 3/3 – T 1/2, G 1/2 
M23 T 1/1 – T 1/2, G 1/2 – T 2/4, G 2/4 
The fractions indicate number of samples with the indicated nucleotide over total number of samples. See text and Figure
1 for variations at other sites than nt 350. –, no lesions of this type available. HPV16 E6 gene variations in cervival cancer 795
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CIN II lesion and invasive cancer, and then occurs a mutation at nt
374 from C to T in CIN II. The reason for this is unclear. We have
not been able to ascertain whether the E6 DNA is integrated or
present in episomal form. In the former situation, the E6 genome
would be subject to the same genomic instability as the cellular
genome of the cancer cell (Mazurenko et al, 1999). Since the E6
variants fail to show importance in the progression of ICC, the
positive association of the M group with clinical malignancy
(Table 1) could then be an epiphenomenon explained probably by
influence of the cancer cells on a residing viral genome, rather
than the reverse conventional hypothesis that different E6 variants
have a different potential to drive progression to invasive cervical
cancer. 
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